Patent ID: 9138465
Filing Date: 2015-09-22
Classification: A61K,A61P,C12N,C12Y

Abstract:
1. A process for producing a pharmaceutical composition for treating mucolipidosis type II or type III, comprising a group of purified lysosomal enzymes as an active ingredient, the process comprising obtaining the group of lysosomal enzymes by performing the following steps: adding to a cell one or more reagents selected from the group consisting of amphiphilic amines, lysosome-tropic amines, ionophores, and V-ATPase inhibitors, followed by culturing; collecting a culture supernatant; and purifying the obtained culture supernatant, wherein the group of purified lysosomal enzymes comprises at least α-mannosidase, α-fucosidase, α-galactosidase, α-glucosidase, β-galactosidase, β-glucosidase, β-hexosaminidase, β-glucuronidase, galactocerebrosidase, and cathepsin, and wherein the purified lysosomal enzymes are not recombinant enzymes.